Paul Peter Tak - 10 Sep 2026 Form 4 Insider Report for Candel Therapeutics, Inc. (CADL)

Reporting relationship: Chief Executive Officer, Director
Issuer ticker: CADL
Reported as of: 10 Sep 2026
Net transaction value: -$3,160,783
SEC form: 4
Accepted by SEC: 11 Sep 2026, 18:12:13 UTC
Prior SEC filing: 28 Jan 2026
Source filing: View source filing
Reporting owner signature: /s/ Charles Schoch, as Attorney-In-Fact for Paul Peter Tak

Key filing fact

Paul Peter Tak filed Form 4 for Candel Therapeutics, Inc. (CADL) on 11 Sep 2026.

Key facts

This page summarizes Paul Peter Tak's Form 4 filing for Candel Therapeutics, Inc. (CADL).
4 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 11 Sep 2026, 18:12.

Change

Previous filing in this sequence was filed on 28 Jan 2026.
Current net transaction value: -$3,160,783.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001873905 Primary reporting owner

Tak Paul Peter

Relationship: Chief Executive Officer, Director
Address: C/O CANDEL THERAPEUTICS, INC., 117 KENDRICK ST., SUITE 450, NEEDHAM
Signature: /s/ Charles Schoch, as Attorney-In-Fact for Paul Peter Tak
Signature date: 11 Sep 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CADL transaction

Common Stock

Options Exercise

Transaction value
Shares: +125,000
Change %: +47%
Price: $1.55^*
Shares after: 393,566
Date: 10 Sep 2026
Ownership: Direct
Footnotes: F1

CADL transaction

Common Stock

Sale

Transaction value: $2,539,893
Shares: -220,866
Change %: -56%
Price: $11.50
Shares after: 172,700
Date: 10 Sep 2026
Ownership: Direct
Footnotes: F1, F2

CADL transaction

Common Stock

Sale

Transaction value: $620,891
Shares: -59,379
Change %: -34%
Price: $10.46
Shares after: 113,321
Date: 11 Sep 2026
Ownership: Direct
Footnotes: F1, F3

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CADL transaction Derivative

Stock Option (Right to Buy)

Options Exercise

Transaction value
Shares: -125,000
Change %: -7.1%
Price: $0.000000^*
Shares after: 1,638,968
Date: 10 Sep 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 125,000
Exercise price: $1.55
Footnotes: F1, F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 4 footnotes

Footnote F1

This transaction reported on this Form 4 was effected pursuant to a 10b5-1 plan adopted on 3/13/2026 and modified on 6/11/2026.

Footnote F2

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.20 to $12.07, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 herein.

Footnote F3

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.86 to $11.39, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 herein.

Footnote F4

25% of this option vested and became exercisable on October 10, 2020, with another 25% vesting on September 14, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter.